Kymera Therapeutics KYMR Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $144.09M+60.2% | $357.01M+197% | $112.95M+2.0% | $335.82M+397% | $89.97M-3.8% | ||
| $506.84M+35.8% | $491.27M+33.3% | $392.73M-10.6% | $329.63M-25.5% | $373.18M-12.6% | ||
| $5.81M+0.1% | $5.8M+0.1% | $5.79M+0.1% | $5.82M-0.4% | $5.81M-0.3% | ||
| $26.5M+48.9% | $22.94M+6.6% | $22.62M+29.8% | $22.88M+66.4% | $17.8M+21.3% | ||
| —— | —— | $0-100% | $0-100% | $20M+885% | ||
| $677.43M+35.2% | $871.21M+70.7% | $528.3M-7.1% | $728.33M+38.6% | $500.95M-6.8% | ||
| $41.62M-15.4% | $43.18M-14.4% | $45.13M-11.9% | $48.57M-6.1% | $49.17M-0.3% | ||
| $41.74M-10.7% | $42.35M-10.7% | $42.95M-10.6% | $46.05M-5.5% | $46.73M-5.3% | ||
| $7.7M+132% | $9.11M+367% | $6.83M— | $4.68M+147% | $3.31M+56.4% | ||
| $894.72M+186% | $771.16M+113% | $473.06M+31.0% | $297.63M+54.7% | $312.34M+39.2% | ||
| $1.67B+81.7% | $1.74B+78.2% | $1.1B+6.5% | $1.13B+36.9% | $918.31M+5.8% | ||
| $12.84M+25.1% | $4.02M-33.0% | $5.51M-15.2% | $5.78M-11.2% | $10.26M+50.7% | ||
| $976K+9.3% | $242K+8.5% | $408K-35.5% | $117K-34.3% | $893K+8.4% | ||
| $0-100% | $22.93M+68.9% | $23.28M+16.3% | $40M+108% | $11.48M-49.3% | ||
| $1.7M+9.1% | $1.82M+19.6% | $1.89M+40.7% | $1.9M+91.5% | $1.56M+37.6% | ||
| $12.03M+3.0% | $11.94M+3.0% | $11.85M+3.0% | $11.77M+3.0% | $11.68M+33.4% | ||
| $1.7M+9.1% | $1.82M+19.6% | $1.89M+40.7% | $1.9M+91.5% | $1.56M+37.6% | ||
| $0— | $11.44M— | $13.96M— | —— | —— | ||
| $62.64M+6.2% | $83.21M+22.8% | $71.58M+7.6% | $87.54M+40.9% | $58.99M+5.1% | ||
| $65.59M-7.9% | $67.03M-7.4% | $68.45M-7.0% | $69.84M-6.7% | $71.18M-6.3% | ||
| $2.85M-17.7% | $3.28M-12.5% | $3.69M+19.7% | $4.11M+113% | $3.47M+51.5% | ||
| $77.62M-6.3% | $78.98M-6.0% | $80.3M-5.7% | $81.6M-5.4% | $82.86M-2.2% | ||
| $1.15M-39.7% | $1.46M-34.3% | $1.8M+3.4% | $2.21M+135% | $1.91M+65.1% | ||
| $129.38M-2.0% | $163.15M+14.6% | $155.79M+9.8% | $159.59M+13.1% | $132.08M-15.9% | ||
| $0— | $0— | $0— | $0— | —— | ||
| $8K+14.3% | $8K+14.3% | $7K0.0% | $7K+16.7% | $7K+16.7% | ||
| $2.68B+66.8% | $2.64B+66.1% | $1.92B+22.2% | $1.87B+42.8% | $1.61B+24.3% | ||
| -$1.14B-38.4% | -$1.07B-41.3% | -$978.98M-43.2% | -$896.81M-44.3% | -$820.19M-41.6% | ||
| -$4.19M-7,131% | $1.8M+221% | $1.5M-22.3% | $279K+113% | -$58K+96.7% | ||
| $1.54B+95.8% | $1.58B+89.0% | $946.26M+6.0% | $971.48M+41.8% | $786.23M+10.5% | ||
| $1.67B+81.7% | $1.74B+78.2% | $1.1B+6.5% | $1.13B+36.9% | $918.31M+5.8% | ||
| $506.84M+35.8% | $491.27M+33.3% | $392.73M-10.6% | $329.63M-25.5% | $373.18M-12.6% | ||
| $7.7M+132% | $9.11M+367% | $6.83M— | $4.68M+147% | $3.31M+56.4% | ||
| $41.74M-10.7% | $42.35M-10.7% | $42.95M-10.6% | $46.05M-5.5% | $46.73M-5.3% | ||
| $894.72M+186% | $771.16M+113% | $473.06M+31.0% | $297.63M+54.7% | $312.34M+39.2% | ||
| $41.74M-10.7% | $42.35M-10.7% | $42.95M-10.6% | $46.05M-5.5% | $46.73M-5.3% | ||
| $7.7M+132% | $9.11M+367% | $6.83M— | $4.68M+147% | $3.31M+56.4% | ||
| $41.74M-10.7% | $42.35M-10.7% | $42.95M-10.6% | $46.05M-5.5% | $46.73M-5.3% | ||
| $7.7M+132% | $9.11M+367% | $6.83M— | $4.68M+147% | $3.31M+56.4% | ||
| $0— | $11.44M— | $13.96M— | —— | —— | ||
| $35.1M+51.8% | $42.27M+21.2% | $28.64M+7.9% | $27.98M+17.6% | $23.12M+44.5% | ||
| $35.1M+51.8% | $42.27M+21.2% | $28.64M+7.9% | $27.98M+17.6% | $23.12M+44.5% | ||
| $976K+9.3% | $242K+8.5% | $408K-35.5% | $117K-34.3% | $893K+8.4% | ||
| $0— | $11.44M— | $13.96M— | —— | —— | ||
| $0— | $11.44M— | $13.96M— | —— | —— | ||
| $82.17M-6.5% | $84.07M-5.8% | $85.89M-4.1% | $87.61M-1.7% | $87.89M-0.3% | ||
| $2.68B+66.8% | $2.64B+66.1% | $1.92B+22.2% | $1.87B+42.8% | $1.61B+24.3% | ||
| $8K+14.3% | $8K+14.3% | $7K0.0% | $7K+16.7% | $7K+16.7% | ||
| $0— | $0— | $0— | $0— | —— | ||
| $1.7M+9.1% | $1.82M+19.6% | $1.89M+40.7% | $1.9M+91.5% | $1.56M+37.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kymera Therapeutics's total assets?
- Kymera Therapeutics (KYMR) holds $1.7B in total assets, up 81.8% year over year.
- How much debt does Kymera Therapeutics have?
- Kymera Therapeutics carries $82.2M in total debt against $1.5B of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Kymera Therapeutics have?
- Kymera Therapeutics holds $144.1M in cash and equivalents.
- Can Kymera Therapeutics cover its short-term obligations?
- Its current ratio is 10.81 — current assets exceed current liabilities.
- Where does Kymera Therapeutics's balance sheet data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
